Literature DB >> 17824497

Melatonin and its receptors: a new class of sleep-promoting agents.

Karl Doghramji1.   

Abstract

Mesh：

Substances：

Year:  2007        PMID： 17824497      PMCID： PMC1978320     

Source DB:  PubMed          Journal:  J Clin Sleep Med        ISSN： 1550-9389            Impact factor:   4.062


× No keyword cloud information.
  57 in total

1.  Disposition kinetics and tolerance of escalating single doses of ramelteon, a high-affinity MT1 and MT2 melatonin receptor agonist indicated for treatment of insomnia.

Authors:  Aziz Karim; Dwain Tolbert; Charlie Cao
Journal:  J Clin Pharmacol       Date:  2006-02       Impact factor: 3.126

2.  An efficacy, safety, and dose-response study of Ramelteon in patients with chronic primary insomnia.

Authors:  Milton Erman; David Seiden; Gary Zammit; Stephen Sainati; Jeffrey Zhang
Journal:  Sleep Med       Date:  2005-11-23       Impact factor: 3.492

3.  The efficacy and safety of the melatonin agonist beta-methyl-6-chloromelatonin in primary insomnia: a randomized, placebo-controlled, crossover clinical trial.

Authors:  Frank P Zemlan; J Jeffery Mulchahey; Martin B Scharf; David W Mayleben; Russell Rosenberg; Alan Lankford
Journal:  J Clin Psychiatry       Date:  2005-03       Impact factor: 4.384

Review 4.  The human circadian system in normal and disordered sleep.

Authors:  Gary S Richardson
Journal:  J Clin Psychiatry       Date:  2005       Impact factor: 4.384

Review 5.  Melatonin: role in gating nocturnal rise in sleep propensity.

Authors:  P Lavie
Journal:  J Biol Rhythms       Date:  1997-12       Impact factor: 3.182

6.  The efficacy and safety of exogenous melatonin for primary sleep disorders. A meta-analysis.

Authors:  Nina Buscemi; Ben Vandermeer; Nicola Hooton; Rena Pandya; Lisa Tjosvold; Lisa Hartling; Glen Baker; Terry P Klassen; Sunita Vohra
Journal:  J Gen Intern Med       Date:  2005-12       Impact factor: 5.128

7.  Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist.

Authors:  Koki Kato; Keisuke Hirai; Keiji Nishiyama; Osamu Uchikawa; Kohji Fukatsu; Shigenori Ohkawa; Yuji Kawamata; Shuji Hinuma; Masaomi Miyamoto
Journal:  Neuropharmacology       Date:  2005-02       Impact factor: 5.250

8.  Effects of exogenous melatonin on sleep: a meta-analysis.

Authors:  Amnon Brzezinski; Mark G Vangel; Richard J Wurtman; Gillian Norrie; Irina Zhdanova; Abraham Ben-Shushan; Ian Ford
Journal:  Sleep Med Rev       Date:  2005-02       Impact factor: 11.609

9.  Phase-shifts of 24-h rhythms of hormonal release and body temperature following early evening administration of the melatonin agonist agomelatine in healthy older men.

Authors:  Rachel Leproult; Anne Van Onderbergen; Mireille L'hermite-Balériaux; Eve Van Cauter; Georges Copinschi
Journal:  Clin Endocrinol (Oxf)       Date:  2005-09       Impact factor: 3.478

10.  Resynchronisation of a diurnal rodent circadian clock accelerated by a melatonin agonist.

Authors:  O Van Reeth; E Olivares; F W Turek; L Granjon; E Mocaer
Journal:  Neuroreport       Date:  1998-06-01       Impact factor: 1.837
View more
  15 in total

Review 1.  Evaluation of current pharmacological treatment options in the management of Rett syndrome: from the present to future therapeutic alternatives.

Authors:  Christopher A Chapleau; Jane Lane; Lucas Pozzo-Miller; Alan K Percy
Journal:  Curr Clin Pharmacol       Date:  2013-11

2.  Electrochemical detection of exogenously administered melatonin in the brain.

Authors:  Elisa Castagnola; Kevin Woeppel; Asiyeh Golabchi; Moriah McGuier; Neharika Chodapaneedi; Julian Metro; I Mitch Taylor; X Tracy Cui
Journal:  Analyst       Date:  2020-02-19       Impact factor: 4.616

3.  No effect by the common gene variant rs10830963 of the melatonin receptor 1B on the association between sleep disturbances and type 2 diabetes: results from the Nord-Trøndelag Health Study.

Authors:  L Olsson; E Pettersen; A Ahlbom; S Carlsson; K Midthjell; V Grill
Journal:  Diabetologia       Date:  2011-03-05       Impact factor: 10.122

4.  Altered sleep architecture and higher incidence of subsyndromal depression in low endogenous melatonin secretors.

Authors:  Shadab Ataur Rahman; Shai Marcu; Leonid Kayumov; Colin Michael Shapiro
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-12-18       Impact factor: 5.270

5.  Ramelteon for insomnia symptoms in a community sample of adults with generalized anxiety disorder: an open label study.

Authors:  Paul K Gross; Rosemary Nourse; Thomas E Wasser
Journal:  J Clin Sleep Med       Date:  2009-02-15       Impact factor: 4.062

6.  Sleep, Melatonin, and the Menopausal Transition: What Are the Links?

Authors:  Shazia Jehan; Giardin Jean-Louis; Ferdinand Zizi; Evan Auguste; Seitikurippu R Pandi-Perumal; Ravi Gupta; Hrayr Attarian; Samy I McFarlane; Rüdiger Hardeland; Amnon Brzezinski
Journal:  Sleep Sci       Date:  2017 Jan-Mar

Review 7.  Synthetic melatoninergic ligands: achievements and prospects.

Authors:  N V Kostiuk; M B Belyakova; D V Leshchenko; V V Zhigulina; M V Miniaev
Journal:  ISRN Biochem       Date:  2014-02-23

Review 8.  COVID-19: Sleep, Circadian Rhythms and Immunity - Repurposing Drugs and Chronotherapeutics for SARS-CoV-2.

Authors:  Allan Giri; Ashokkumar Srinivasan; Isaac Kirubakaran Sundar
Journal:  Front Neurosci       Date:  2021-06-18       Impact factor: 4.677

9.  Ramelteon combined with an α1-blocker decreases nocturia in men with benign prostatic hyperplasia.

Authors:  Takashi Kawahara; Satoshi Morita; Hiroki Ito; Hideyuki Terao; Ryoko Sakata; Hitoshi Ishiguro; Katsuyuki Tanaka; Hiroshi Miyamoto; Junichi Matsuzaki; Yoshinobu Kubota; Hiroji Uemura
Journal:  BMC Urol       Date:  2013-06-12       Impact factor: 2.264

10.  Prophylactic Role of Oral Melatonin Administration on Neurogenesis in Adult Balb/C Mice during REM Sleep Deprivation.

Authors:  Gabriela López-Armas; Mario Eduardo Flores-Soto; Verónica Chaparro-Huerta; Luis Felipe Jave-Suarez; Sofía Soto-Rodríguez; Iryna Rusanova; Dario Acuña-Castroviejo; Oscar González-Perez; Rocío Elizabeth González-Castañeda
Journal:  Oxid Med Cell Longev       Date:  2016-08-07       Impact factor: 6.543
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.